(CGC) Canopy Growth - Overview
Exchange: NASDAQ •
Country: Canada •
Currency: USD •
Type: Common Stock •
ISIN: CA1380351009
Stock: Dried Flower, Extracts, Edibles, Vapes, Beverages
Total Rating 12
Risk 40
Buy Signal -2.69
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 103% |
| Relative Tail Risk | -24.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.16 |
| Alpha | -66.87 |
| Character TTM | |
|---|---|
| Beta | 1.520 |
| Beta Downside | 1.357 |
| Drawdowns 3y | |
|---|---|
| Max DD | 96.70% |
| CAGR/Max DD | -0.66 |
Description: CGC Canopy Growth January 01, 2026
Canopy Growth Corp (NASDAQ: CGC) and its subsidiaries produce, distribute, and sell cannabis, hemp, and related products across Canada, Germany, and Australia, organized into four operating segments: Canada Cannabis, International Markets Cannabis, Storz & Bickel, and This Works.
The product lineup spans dried flower, pre-rolled joints, extracts, soft-gel capsules, edibles (e.g., gummies), vaporizers, oils, and cannabis-infused beverages, marketed under brands such as Tweed, 7ACRES, Deep Space, HiWay, Maitri, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Wana, Claybourne, DOJA, LivRelief, Ace Valley, and Vert.
Key recent data points: CGC reported FY 2023 revenue of roughly $1.1 billion but posted a net loss of $1.2 billion, reflecting high operating costs and ongoing integration of its 2022 Constellation Brands partnership; the Canadian adult-use market grew ~15 % YoY in 2023, while German medical-cannabis sales are expanding at an estimated 20 % annual rate, both of which are primary growth drivers for CGC’s international segment.
For a deeper quantitative assessment of CGC’s valuation metrics, you may find the ValueRay analysis useful.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -385.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA 4.59 > 1.0 |
| NWC/Revenue: 130.9% < 20% (prev 39.35%; Δ 91.55% < -1%) |
| CFO/TA -0.08 > 3% & CFO -88.4m > Net Income -385.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.50 > 1.5 & < 3 |
| Outstanding Shares: last quarter (274.0m) vs 12m ago 215.6% < -2% |
| Gross Margin: 26.77% > 18% (prev 0.31%; Δ 2646 % > 0.5%) |
| Asset Turnover: 24.20% > 50% (prev 22.76%; Δ 1.44% > 0%) |
| Interest Coverage Ratio: -7.28 > 6 (EBITDA TTM -294.0m / Interest Expense TTM 46.0m) |
Altman Z'' -15.00
| A: 0.34 (Total Current Assets 445.8m - Total Current Liabilities 81.1m) / Total Assets 1.07b |
| B: -10.26 (Retained Earnings -10.97b / Total Assets 1.07b) |
| C: -0.29 (EBIT TTM -334.7m / Avg Total Assets 1.15b) |
| D: -5.63 (Book Value of Equity -1.88b / Total Liabilities 333.8m) |
| Altman-Z'' Score: -39.06 = D |
Beneish M -3.62
| DSRI: 0.65 (Receivables 26.9m/41.9m, Revenue 278.6m/280.5m) |
| GMI: 1.18 (GM 26.77% / 31.47%) |
| AQI: 0.72 (AQ_t 0.31 / AQ_t-1 0.44) |
| SGI: 0.99 (Revenue 278.6m / 280.5m) |
| TATA: -0.28 (NI -385.9m - CFO -88.4m) / TA 1.07b) |
| Beneish M-Score: -3.62 (Cap -4..+1) = AAA |
What is the price of CGC shares?
As of February 06, 2026, the stock is trading at USD 1.08 with a total of 19,515,352 shares traded.
Over the past week, the price has changed by -2.70%, over one month by -9.24%, over three months by -5.26% and over the past year by -57.31%.
Over the past week, the price has changed by -2.70%, over one month by -9.24%, over three months by -5.26% and over the past year by -57.31%.
Is CGC a buy, sell or hold?
Canopy Growth has received a consensus analysts rating of 2.50.
Therefor, it is recommend to sell CGC.
- StrongBuy: 0
- Buy: 2
- Hold: 4
- Sell: 1
- StrongSell: 3
What are the forecasts/targets for the CGC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 1.8 | 69.4% |
| Analysts Target Price | 1.8 | 69.4% |
| ValueRay Target Price | 0.5 | -50.9% |
CGC Fundamental Data Overview February 03, 2026
Market Cap CAD = 601.9m (440.5m USD * 1.3664 USD.CAD)
P/E Forward = 20.3666
P/S = 1.5811
P/B = 0.7746
Revenue TTM = 278.6m CAD
EBIT TTM = -334.7m CAD
EBITDA TTM = -294.0m CAD
Long Term Debt = 226.3m CAD (from longTermDebt, last quarter)
Short Term Debt = 1.85m CAD (from shortTermDebt, last quarter)
Debt = 254.6m CAD (from shortLongTermDebtTotal, last quarter)
Net Debt = -43.5m CAD (from netDebt column, last quarter)
Enterprise Value = 558.4m CAD (601.9m + Debt 254.6m - CCE 298.1m)
Interest Coverage Ratio = -7.28 (Ebit TTM -334.7m / Interest Expense TTM 46.0m)
EV/FCF = -5.81x (Enterprise Value 558.4m / FCF TTM -96.1m)
FCF Yield = -17.22% (FCF TTM -96.1m / Enterprise Value 558.4m)
FCF Margin = -34.51% (FCF TTM -96.1m / Revenue TTM 278.6m)
Net Margin = -138.5% (Net Income TTM -385.9m / Revenue TTM 278.6m)
Gross Margin = 26.77% ((Revenue TTM 278.6m - Cost of Revenue TTM 204.0m) / Revenue TTM)
Gross Margin QoQ = 32.85% (prev 25.01%)
Tobins Q-Ratio = 0.52 (Enterprise Value 558.4m / Total Assets 1.07b)
Interest Expense / Debt = 3.46% (Interest Expense 8.80m / Debt 254.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -264.4m (EBIT -334.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.50 (Total Current Assets 445.8m / Total Current Liabilities 81.1m)
Debt / Equity = 0.35 (Debt 254.6m / totalStockholderEquity, last quarter 736.0m)
Debt / EBITDA = 0.15 (negative EBITDA) (Net Debt -43.5m / EBITDA -294.0m)
Debt / FCF = 0.45 (negative FCF - burning cash) (Net Debt -43.5m / FCF TTM -96.1m)
Total Stockholder Equity = 575.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.52% (Net Income -385.9m / Total Assets 1.07b)
RoE = -67.00% (Net Income TTM -385.9m / Total Stockholder Equity 575.9m)
RoCE = -41.72% (EBIT -334.7m / Capital Employed (Equity 575.9m + L.T.Debt 226.3m))
RoIC = -29.61% (negative operating profit) (NOPAT -264.4m / Invested Capital 893.2m)
WACC = 8.91% (E(601.9m)/V(856.5m) * Re(11.52%) + D(254.6m)/V(856.5m) * Rd(3.46%) * (1-Tc(0.21)))
Discount Rate = 11.52% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 81.79%
Fair Price DCF = unknown (Cash Flow -96.1m)
EPS Correlation: 27.92 | EPS CAGR: 22.83% | SUE: 0.13 | # QB: 0
Revenue Correlation: -84.33 | Revenue CAGR: -18.10% | SUE: -0.26 | # QB: 0
EPS next Year (2027-03-31): EPS=0.09 | Chg30d=-0.080 | Revisions Net=+1 | Growth EPS=+169.2% | Growth Revenue=+5.7%
P/E Forward = 20.3666
P/S = 1.5811
P/B = 0.7746
Revenue TTM = 278.6m CAD
EBIT TTM = -334.7m CAD
EBITDA TTM = -294.0m CAD
Long Term Debt = 226.3m CAD (from longTermDebt, last quarter)
Short Term Debt = 1.85m CAD (from shortTermDebt, last quarter)
Debt = 254.6m CAD (from shortLongTermDebtTotal, last quarter)
Net Debt = -43.5m CAD (from netDebt column, last quarter)
Enterprise Value = 558.4m CAD (601.9m + Debt 254.6m - CCE 298.1m)
Interest Coverage Ratio = -7.28 (Ebit TTM -334.7m / Interest Expense TTM 46.0m)
EV/FCF = -5.81x (Enterprise Value 558.4m / FCF TTM -96.1m)
FCF Yield = -17.22% (FCF TTM -96.1m / Enterprise Value 558.4m)
FCF Margin = -34.51% (FCF TTM -96.1m / Revenue TTM 278.6m)
Net Margin = -138.5% (Net Income TTM -385.9m / Revenue TTM 278.6m)
Gross Margin = 26.77% ((Revenue TTM 278.6m - Cost of Revenue TTM 204.0m) / Revenue TTM)
Gross Margin QoQ = 32.85% (prev 25.01%)
Tobins Q-Ratio = 0.52 (Enterprise Value 558.4m / Total Assets 1.07b)
Interest Expense / Debt = 3.46% (Interest Expense 8.80m / Debt 254.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -264.4m (EBIT -334.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.50 (Total Current Assets 445.8m / Total Current Liabilities 81.1m)
Debt / Equity = 0.35 (Debt 254.6m / totalStockholderEquity, last quarter 736.0m)
Debt / EBITDA = 0.15 (negative EBITDA) (Net Debt -43.5m / EBITDA -294.0m)
Debt / FCF = 0.45 (negative FCF - burning cash) (Net Debt -43.5m / FCF TTM -96.1m)
Total Stockholder Equity = 575.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.52% (Net Income -385.9m / Total Assets 1.07b)
RoE = -67.00% (Net Income TTM -385.9m / Total Stockholder Equity 575.9m)
RoCE = -41.72% (EBIT -334.7m / Capital Employed (Equity 575.9m + L.T.Debt 226.3m))
RoIC = -29.61% (negative operating profit) (NOPAT -264.4m / Invested Capital 893.2m)
WACC = 8.91% (E(601.9m)/V(856.5m) * Re(11.52%) + D(254.6m)/V(856.5m) * Rd(3.46%) * (1-Tc(0.21)))
Discount Rate = 11.52% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 81.79%
Fair Price DCF = unknown (Cash Flow -96.1m)
EPS Correlation: 27.92 | EPS CAGR: 22.83% | SUE: 0.13 | # QB: 0
Revenue Correlation: -84.33 | Revenue CAGR: -18.10% | SUE: -0.26 | # QB: 0
EPS next Year (2027-03-31): EPS=0.09 | Chg30d=-0.080 | Revisions Net=+1 | Growth EPS=+169.2% | Growth Revenue=+5.7%